CEFALY Technology, the developers of the very first FDA-approved trigeminal nerve stimulation gadget specifically licensed to prevent migraine attacks, releases information about the compliance of the device by patients struggling with migraine and compares it with the compliance of preventive migraine headache medication.

CEFALY Technology gathered information on 14,745 migraine headache patients who got the device in between March 2014 and October 2015, a period of 19 months. If all clients where using the device daily, in accordance to their physician's suggestion, the compliance would be 100 per cent, but the actual electrode usage exposes that the compliance is 72.4 per cent, which is twice the compliance rate generally reported for oral preventive migraine medication.

"This is an excellent verification that the Cefaly is a better solution than medications for migraine headache prophylaxis", said Dr. Rigaux, Chief Executive Officer of CEFALY Technology, the maker of the gadget. "Not only does the high security and the unlikely yet small adverse effects discuss the high compliance, the patient complete satisfaction for the effectiveness does too. With the recent released clinical trials and the most recent data from numerous clinical trials in the US, this compliance information shows that Cefaly is becoming the first-line treatment for clients who deal with frequent migraine.".

In March 2014, the FDA authorized Cefaly. The prescription-only, headband-like, device, utilizes small electrical impulses to stimulate the trigeminal nerve to reduce the frequency and intensity of migraines. At the time, the FDA reached its choice utilizing information from a randomized double blinded medical trial implemented in five university centers; along with a client complete satisfaction study of 2,313 Cefaly users.

Cefaly is now offered at the Boots Pharmacy outlet in Dubai Mall and the Boots Pharmacy outlet in Abu Dhabi Mall.